{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T04:47:30Z","timestamp":1768452450689,"version":"3.49.0"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"13","license":[{"start":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T00:00:00Z","timestamp":1711670400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,3,29]]},"abstract":"<jats:p>Non-ischemic dilated cardiomyopathy (NIDCM) is characterized by left ventricular dilatation and contractile dysfunction with severe morbidity and mortality. Sodium glucose cotransporter type 2 (SGLT2) inhibitors significantly reduce cardiovascular events for heart failure patients. We performed to investigate the impact of combined administration of SGLT2 inhibitors on cardiac structure and function in NIDCM patients undergoing conventional therapy. A total of 50 newly diagnosed NIDCM patients received conventional medical therapy, with 23 receiving dapagliflozin 10mg\/day in addition (SGLT2i group) and the remaining 27 only receiving conventional therapy (non-SGLT2i group). After 12 months outpatient follow-up, NIDCM patients treated with conventional therapy alone showed a significant reduction of left ventricular end-diastolic dimensions (LVEDd), left ventricular end-systolic dimensions (LVESd), left ventricular end-diastolic volumes (LVEDV), left ventricular end-systolic volumes (LVESV), left ventricular end-diastolic volume index (LVEDVi) and left ventricular end-systolic volume index (LVESVi), while an increase in fractional shortening (FS) and left ventricular ejection fraction (LVEF). Patients receiving dapagliflozin combined with conventional treatment also demonstrated a significant reduction in left ventricular dimensions and volumes, and a marked increase in cardiac function. In non-SGLT2i groups, the % change in LVEDd, LVESd, LVEDV, LVESV, LVEDVi, LVESVi, FS and LVEF was \u22122.8%, \u22124.6%, \u22126.2%, \u221210.1%, \u22126.1%, \u221210.1%, +9.7%, +11%. A greater absolute % fall in left ventricular volume in SGLT2i groups compared to non-SGLT2i groups resulted in a significant improvement in cardiac function. The results showed that SGLT2i combined with conventional therapy has a better beneficial effect on left ventricular volumes and cardiac function in NIDCM patients.<\/jats:p>","DOI":"10.1097\/md.0000000000037579","type":"journal-article","created":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T18:03:25Z","timestamp":1711735405000},"page":"e37579","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Effect of dapagliflozin on left ventricular structure and function in patients with non-ischemic dilated cardiomyopathy: An observational study"],"prefix":"10.1097","volume":"103","author":[{"given":"Jun","family":"Hong","sequence":"first","affiliation":[{"name":"Department of Cardiology, Ningbo Hangzhou Bay Hospital, Ningbo, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6626-459X","authenticated-orcid":false,"given":"Lei","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Ningbo Hangzhou Bay Hospital, Ningbo, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nake","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Ningbo Hangzhou Bay Hospital, Ningbo, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuechen","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Ningbo Hangzhou Bay Hospital, Ningbo, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianan","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Ningbo Hangzhou Bay Hospital, Ningbo, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250503","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1161\/01.CIR.93.5.841","article-title":"Report of the 1995 World Health Organization\/International Society and federation of cardiology task force on the definition and classification of cardiomyopathies.","volume":"93","author":"Richardson","year":"1996","journal-title":"Circulation"},{"key":"R2-20250503","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1016\/j.jacc.2016.03.590","article-title":"The diagnosis and evaluation of dilated cardiomyopathy.","volume":"67","author":"Japp","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"R3-20250503","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/nrcardio.2013.105","article-title":"Dilated cardiomyopathy: the complexity of a diverse genetic architecture.","volume":"10","author":"Hershberger","year":"2013","journal-title":"Nat Rev Cardiol"},{"key":"R4-20250503","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1161\/CIRCEP.111.962050","article-title":"Dilated cardiomyopathy.","volume":"6","author":"Lakdawala","year":"2013","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"R5-20250503","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1007\/s10741-020-09940-0","article-title":"Non-ischemic dilated cardiomyopathy and cardiac fibrosis.","volume":"26","author":"Cojan-Minzat","year":"2021","journal-title":"Heart Fail Rev"},{"key":"R6-20250503","doi-asserted-by":"crossref","first-page":"1605064","DOI":"10.3389\/ijph.2022.1605064","article-title":"System dynamic model simulates the growth trend of diabetes mellitus in Chinese Population: implications for future urban public health governance.","volume":"67","author":"Li","year":"2022","journal-title":"Int J Public Health"},{"key":"R7-20250503","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1146\/annurev-physiol-031620-095920","article-title":"Effects of SGLT2 inhibitors on kidney and cardiovascular function.","volume":"83","author":"Vallon","year":"2021","journal-title":"Annu Rev Physiol"},{"key":"R8-20250503","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1111\/dom.14452","article-title":"High-dose sodium-glucose co-transporter-2 inhibitors are superior in type 2 diabetes: a meta-analysis of randomized clinical trials.","volume":"23","author":"Shi","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"R9-20250503","doi-asserted-by":"crossref","first-page":"dgaa586","DOI":"10.1210\/clinem\/dgaa586","article-title":"Clinical adverse events of high-dose vs low-dose sodium-glucose cotransporter 2 Inhibitors in Type 2 Diabetes: a meta-analysis of 51 Randomized Clinical Trials.","volume":"105","author":"Shi","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"R10-20250503","doi-asserted-by":"crossref","first-page":"1011429","DOI":"10.3389\/fcvm.2022.1011429","article-title":"Benefits of SGLT2 inhibitors in arrhythmias.","volume":"9","author":"Gao","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"R11-20250503","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/ehf2.14298","article-title":"The cardiovascular effects of SGLT2 inhibitors, RAS inhibitors, and ARN inhibitors in heart failure.","volume":"10","author":"Ji","year":"2023","journal-title":"ESC Heart Fail"},{"key":"R12-20250503","first-page":"1461","article-title":"Dapagliflozin protects against dilated cardiomyopathy progression by targeting NLRP3 inflammasome activation.","volume":"396","author":"Hu","year":"2023","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"R13-20250503","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1007\/s10554-020-02122-x","article-title":"Association of type 2 diabetes mellitus with the development of new-onset atrial fibrillation in patients with non-ischemic dilated cardiomyopathy: impact of SGLT2 inhibitors.","volume":"37","author":"Tanaka","year":"2021","journal-title":"Int J Cardiovasc Imaging"},{"key":"R14-20250503","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1210\/clinem\/dgab834","article-title":"Beneficial effect of sodium-glucose co-transporter 2 inhibitors on left ventricular function.","volume":"107","author":"Shi","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"R15-20250503","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1002\/ejhf.1867","article-title":"Efficacy and safety of sodium-glucose co-transporter 2 inhibition according to left ventricular ejection fraction in DAPA-HF.","volume":"22","author":"Dewan","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"R16-20250503","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications.","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"key":"R17-20250503","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1161\/CIRCULATIONAHA.120.052186","article-title":"Effect of empagliflozin on left ventricular volumes in patients with Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF).","volume":"143","author":"Lee","year":"2021","journal-title":"Circulation"},{"key":"R18-20250503","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/j.jacc.2019.01.056","article-title":"Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics.","volume":"73","author":"Santos-Gallego","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"R19-20250503","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s12933-019-0964-4","article-title":"Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet\/streptozotocin-induced diabetic rats.","volume":"18","author":"Shao","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"R20-20250503","doi-asserted-by":"crossref","first-page":"108053","DOI":"10.1016\/j.pharmthera.2021.108053","article-title":"Targeting the NLRP3 inflammasome in cardiovascular diseases.","volume":"236","author":"Toldo","year":"2022","journal-title":"Pharmacol Ther"},{"key":"R21-20250503","doi-asserted-by":"crossref","first-page":"109024","DOI":"10.1016\/j.intimp.2022.109024","article-title":"SGLT2 inhibitor, canagliflozin, ameliorates cardiac inflammation in experimental autoimmune myocarditis.","volume":"110","author":"Long","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"R22-20250503","doi-asserted-by":"crossref","first-page":"e54442","DOI":"10.1371\/journal.pone.0054442","article-title":"Effects of SGLT2 inhibition in human kidney proximal tubular cells--renoprotection in diabetic nephropathy?","volume":"8","author":"Panchapakesan","year":"2013","journal-title":"PLoS One"},{"key":"R23-20250503","first-page":"171","article-title":"The neuroendocrinology of congestive heart failure.","volume":"13","author":"Opie","year":"2002","journal-title":"Cardiovasc J S Afr"},{"key":"R24-20250503","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s12933-018-0775-z","article-title":"Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure.","volume":"17","author":"Soga","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"R25-20250503","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12933-019-0849-6","article-title":"The sodium-glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats.","volume":"18","author":"Lee","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"R26-20250503","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12933-019-0914-1","article-title":"Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction.","volume":"18","author":"Zhang","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"R27-20250503","doi-asserted-by":"crossref","first-page":"171","DOI":"10.23736\/S2724-5683.21.05736-7","article-title":"Contemporary etiology and prognosis of dilated non-ischemic cardiomyopathy.","volume":"70","author":"Manca","year":"2022","journal-title":"Minerva Cardiol Angiol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000037579","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T23:01:28Z","timestamp":1746313288000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000037579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,29]]},"references-count":27,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000037579","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,29]]}}}